烧伤疼痛：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

市场概览

• 预计到 2035 年，德国烧伤疼痛治疗市场将从 6,500 万美元成长到 1.25 亿美元，复合年增长率将达到 6-7%。
• 义大利的烧烫伤患者人数呈现稳定成长趋势，儘管增幅较低（年均复合成长率约 1%）。

烧伤疼痛概述

烧伤疼痛是一种极为严重、复杂且动态的神经发炎性疾病，其特征是组织破坏导致的强烈伤害性刺激和受损神经末梢产生的神经病变讯号同时存在。其病理生理机转是由严重的发炎级联反应触发，导致周边敏化（原发性痛觉过敏）和持续性中枢神经系统敏化（次发性痛觉过敏）。

临床上，烧伤疼痛表现极为多样，需要明确地分为以下几类：

1. 背景疼痛（持续性、发炎性）

2. 突发性疼痛（阵发性加重）

3. 与手术相关的疼痛（创伤护理、清创、移植过程中的剧烈疼痛）

急性疼痛管理不足与长期併发症（包括慢性神经病变疼痛和创伤后压力症候群 (PTSD)）密切相关，因此早期有效干预至关重要。

现代治疗模式正从鸦片类药物单一疗法转向包含以下方面的多面向镇痛方法：

• 用于治疗急性疼痛和手术相关疼痛的鸦片类药物
• 非类固醇抗发炎药和对乙酰胺酚用于抑制炎症
• 加巴喷丁类药物用于调节神经病变疼痛
• NMDA 受体拮抗剂（如氯胺酮）用于治疗严重疼痛，并具有减少鸦片类药物用量的效果。

在高级烧伤治疗中，以下技术正日益整合应用：

• 局部麻醉
• α2促效剂用于镇静和缓解焦虑（例如，Dexmedetomidine）
• 非药物疗法，例如基于虚拟实境（VR）的分心疗法，旨在应对心理负担。

这种多方面、以患者为中心的治疗方法体现了需要同时管理烧伤疼痛的生理和心理层面。

主要亮点

• 烧伤疼痛是一个高强度、以治疗主导的治疗领域，治疗需求与发病率的关係比与盛行率的关係更为密切。
• 义大利每年烧伤病例数预计将缓慢成长（年复合成长率为 1%），从 188,000 例增加至 204,000 例，反映出疾病负担稳定但持续存在。

格式化和更新讯息

• 详细报告（PDF）
• 市场预测模型（基于微软Excel）
• 流行病学数据（MS Excel，互动式工具）
• 高阶主管洞察（PPT简报）
• 其他功能：定期更新、自订和顾问支援。
• 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

• 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
• 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
• 未来十年市场收入和病患份额的预测是多少？
• 哪些因素对市场趋势影响最大？
• 受访专家对目前和新兴的治疗方法有何看法？
• 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
• 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
• 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

• G8
  • 我们
  • EU5
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
  • 日本
  • 中国

大公司

• Shanghai Bao Pharmaceuticals Co.

目录

第一章：主要调查结果和分析师说明

• 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

• 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

• 重点
• 发病率/盛行率
• 已确诊并接受药物治疗的患者人数
• 合併症
• 其他相关患者群

第四章 市场规模及预测

• 重点
• 市场驱动因素与限制因素
• 按药物分类的趋势
• 各国具体趋势

第五章 竞争情势

• 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
• 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期管道

第六章：未满足的需求与TPP分析

• 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
• TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

Burn Pain Market Outlook

Thelansis's "Burn Pain Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Burn Pain treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Burn Pain Overview

Burn pain is a uniquely severe, complex, and dynamic neuroinflammatory condition characterized by the coexistence of intense nociceptive input from tissue destruction and neuropathic signaling from damaged nerve endings. The pathophysiology is driven by profound inflammatory cascades, resulting in peripheral sensitization (primary hyperalgesia) and sustained central nervous system sensitization (secondary hyperalgesia).

Clinically, burn pain is highly heterogeneous and requires clear stratification into:

1. Background pain (persistent, inflammatory)

2. Breakthrough pain (episodic exacerbations)

3. Procedural pain (severe pain during wound care, debridement, and grafting)

Inadequate acute pain control is strongly associated with long-term complications, including chronic neuropathic pain and post-traumatic stress disorder (PTSD), making early and effective intervention critical.

The modern treatment paradigm has shifted away from opioid monotherapy toward a multimodal analgesic approach, incorporating:

• Opioids for acute and procedural pain
• NSAIDs and acetaminophen for inflammatory control
• Gabapentinoids for neuropathic modulation
• NMDA receptor antagonists (e.g., ketamine) for severe pain and opioid-sparing effects

Advanced burn care increasingly integrates:

• Regional anesthesia techniques
• Alpha-2 agonists (e.g., dexmedetomidine) for sedation and anxiolysis
• Non-pharmacological interventions, such as virtual reality (VR)-based distraction therapy, to address psychological burden

This multimodal, patient-centric approach reflects the need to manage both the physiological and psychological dimensions of burn pain.

Key Highlights

• Burn pain represents a high-intensity, procedure-driven therapeutic area, where treatment demand is closely linked to incidence rather than prevalence.
• In Italy, the annual burn incidence population is expected to grow modestly (1% CAGR), increasing from 188K to 204K cases, reflecting stable but persistent disease burden.

Market Overview

• The burn pain market in Germany is projected to grow from $65M to $125M by 2035, reflecting a robust CAGR of 6-7%
• The burn patient population shows low but steady growth (~1% CAGR) in Italy

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Shanghai Bao Pharmaceuticals Co.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)